P1354: CRISPR/CAS9 GENE EDITING OF IMMUNE CHECKPOINT RECEPTOR NKG2A IMPROVES THE ANTI-LEUKEMIC EFFICACY OF PRIMARY CD33-TARGETING CAR-NK CELLS.
Main Authors: | Nawid Albinger, Tobias Bexte, Ahmad Al-Ajami, Philipp Wendel, Leon Buchinger, Alec Gessner, Jamal Alzubi, Vinzenz Särchen, Meike Vogler, Raj Bhayadia, Jan-Henning Klusmann, Nina Möker, Toni Cathomen, Michael A. Rieger, Katharina Imkeller, Evelyn Ullrich |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-08-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000972304.71265.f8 |
Similar Items
-
Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy
by: Philipp Wendel, et al.
Published: (2021-03-01) -
CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma
by: Tobias Bexte, et al.
Published: (2022-12-01) -
Immunotherapy with NK cells: recent developments in gene modification open up new avenues
by: Lisa Marie Reindl, et al.
Published: (2020-01-01) -
Characterization of BV6-Induced Sensitization to the NK Cell Killing of Pediatric Rhabdomyosarcoma Spheroids
by: Vinzenz Särchen, et al.
Published: (2023-03-01) -
The travels of ibn battuta A.D. 1325-1354 /
by: Ibn Batuta, 1304-1377, et al.
Published: (1994)